C-reactive protein, atherosclerosis and cardiovascular disease. An update

Recent epidemiological data have documented associations between C-reactive protein (CRP), the prototypical acute phase response protein, and cardiovascular disease in general population. Given the lipoprotein binding and complement activation of CRP and its localization in atherosclerotic vessels, there is a strong likelihood that CRP may be involved in the atherosclerotic process. Statin therapy seems to have action anti-atherosclerosis by inhibiting vascular atherosclerotic inflammation: clinical trials are needed. This review would be an update on the topic.